Assessment of contralateral mammary gland dose in the treatment of breast cancer using accelerated hypofractionated radiotherapy

作     者：Maria Tolia Kalliopi Platoni Andreas Foteineas Maria-Aggeliki Kalogeridi Anna Zygogianni Nikolaos Tsoukalas Mariangela Caimi Niki Margari Maria Dilvoi Panagiotis Pantelakos John Kouvaris Vassilis Kouloulias 

作者机构：1st and 2nd Department of RadiologyRadiation Oncology UnitMedical SchoolAthens 12462Greece Oncology Clinic401 Military HospitalAthens 11525Greece Department of Radiation OncologySan Raffaele HospitalMilan 20132Italy Department of CytologyMedical SchoolAthens 12462Greece 

出 版 物：《World Journal of Radiology》 (世界放射学杂志（英文版）（电子版）)

年 卷 期：2011年第3卷第9期

页      面：233-240页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Breast cancer Hypofractionation Contralateral breast Dose calculation 

摘      要：AIM:To measure the dose distribution,related to the treatment planning calculations,in the contralateral mammary gland of breast cancer patients treated with accelerated hypofractionated 3-dimensional conformal ***:Thirty-four prospectively selected female patients with right breast cancer (pN0,negative surgical margins) were treated with breast-conserving surgery.A total dose of 42.5 Gy (2.66 Gy/fraction) was prescribed;it was requested that planning target volumes be covered by the 95% isodose *** contralateral mam-mary gland was defined on CT *** dose received was evaluated by dose volume ***:The measured contralateral breast doses were:(1) Dose maximum:290-448 cGy [Equivalent (Eq) 337-522 cGy];(2) Mean dose:45-70 cGy (Eq 524815 cGy);and (3) Median dose:29-47 cGy (337-547 cGy) for total primary breast dose of 42.5 Gy in 16 equal *** spearman rho correlation showed statistical significance between the contralateral breast volume and maximum dose (P=0.0292),as well as mean dose (P=0.0025) and median dose (P=0.046) to the ***:Minimizing the dose to the contralateral breast has to be one of the priorities of the radiation oncologist when using short schedules because of the radiosensitivity of this organ at *** study is necessary to assess the long-term clinical impact of this schedule.